Leah Lawrence on Muck Rack

Leah Lawrence

Verified
Lewes
As seen in: Wiley Online Library, MedPage Today, Genetic Literacy Project, NewsBreak, Ash Publications, Modern Medicine, MedCentral, ONCOLOGY journal, Centre for International Governance Innovation, CURE Magazine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Leah

Contact Leah, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

EZH2 inhibitor tazemetostat voluntarily withdrawn from market

|
By Leah Lawrence Verified
| Wiley Online Library Verified
Earlier this year, Ipsen voluntarily withdrew its EZH2 inhibitor tazemetostat for all indications from all markets.1 The US Food and Drug Administration (FDA) approved tazemetostat for advanced epithelioid sarcoma in January 2020.2 In June 2020, it received accelerated approval for relapsed or refractory follicular lymphoma in patients positive for an EZH2 mutation who had received at least two prior systemic therapies.3 Under the accelerated approval pathway, the FDA required a confirmatory...
Open in Who Shared Issue with article?

Phase 3 Data Show Gene Test May Identify Breast Cancer Patients Who Can Skip Chemotherapy

|
By Leah Lawrence Verified
| Oncology News Central Verified
Patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer with tumors that have a low risk-of-recurrence (ROR) score on the Prosigna 50-gene test were able to safely avoid adjuvant chemotherapy, according to results of the phase 3 OPTIMA trial presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 500). “We have shown that patients with low ROR score tumors gain minimum, if any, chemotherapy benefit,” said study presenter Robert C.
Open in Who Shared Issue with article?

For First Time, Definitive Standard Established for Low-Grade Serous Ovarian Carcinoma

|
By Leah Lawrence Verified
| Oncology News Central Verified
Letrozole monotherapy failed to demonstrate noninferiority to chemotherapy followed by letrozole in patients with stage II–IV low-grade serous ovarian carcinoma (LGSOC), according to results from the NRG-GY019 trial that were presented at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer (LBA02).
Open in Who Shared Issue with article?
See all 2,106 licensed articles (2,256 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified